Pegram, Mark D.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 11,500

Trastuzumab emtansine for HER2-positive advanced breast cancer

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 3,834

Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer

Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 1,326

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Powell, J. E., Pegram, M. D., & Slamon, D. J. (2006) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 245

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., et al. (2017) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 193

Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation

Wang, J.-H., Forterre, A. V., Zhao, J., Frimannsson, D. O., Delcayre, A., Antes, T. J., Efron, B., Jeffrey, S. S., Pegram, M. D., & Matin, A. C. (2018) · Molecular Cancer Therapeutics

Extracellular vesicles in diseaseRNA Interference and Gene Delivery

Cited by 181

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients

Hurley, J., Reis, I. M., Rodgers, S. E., Gomez-Fernandez, C., Wright, J., Leone, J. P., Larrieu, R., & Pegram, M. D. (2013) · Breast Cancer Research and Treatment

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 83

SOPHIA primary analysis: a phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)

Rugo, H. S., Im, S.-A., Wright, G. L. S., Escriva-de-Romani, S., DeLaurentiis, M., Cortes, J., Bahadur, S. W., Haley, B. B., Oyola, R. H., Riseberg, D. A., et al. (2019) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 80

Extracellular Vesicle–Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity

Forterre, A. V., Wang, J.-H., Delcayre, A., Kim, K., Green, C., Pegram, M. D., Jeffrey, S. S., & Matin, A. C. (2020) · Molecular Cancer Therapeutics

Extracellular vesicles in diseaseRNA Interference and Gene Delivery

Cited by 62